TABLE 5.

Associations between LP urine CTX or conditional change in CTX, in the vitamin D–supplemented group, placebo group, or combined, and maternal lumbar spine and total hip area, BMC, and aBMD¹

	Total population			Placebo			1000 IU cholecalciferol/d
	n	β (95% CI)	P value	n	β (95% CI)	P value	n	β (95% CI)	P value
LP CTX2
Lumbar spine
Bone area, cm2	283	−0.34 (−0.96, 0.29)	0.29	135	−0.73 (−1.697, 0.235)	0.14	148	−0.08 (−0.92, 0.80)	0.86
BMC, g	283	−1.17 (−2.29, −0.04)	0.04	135	−1.30 (−2.972, 0.377)	0.13	148	−1.11 (−2.69, 0.46)	0.17
aBMD, g/cm2	283	−0.015 (−0.027, −0.003)	0.02	135	−0.009 (−0.028, 0.010)	0.34	148	−0.019 (−0.036, −0.003)	0.03
Total hip
Bone area, cm2	279	−0.32 (−0.70, 0.06)	0.10	133	−0.32 (−0.94, 0.29)	0.30	146	−0.37 (−0.85, 0.11)	0.13
BMC, g	279	−0.68 (−1.21, −0.14)	0.01	133	−0.51 (−1.31, 0.30)	0.22	146	−0.87 (−1.62, −0.13)	0.02
aBMD, g/cm2	279	−0.012 (−0.02, −0.00)	0.05	133	−0.004 (−0.022, 0.013)	0.61	146	−0.017 (−0.033, −0.002)	0.03
Δ CTX3
Lumbar spine
Bone area, cm2	226	−0.23 (−0.92, 0.45)	0.50	109	−0.86 (−1.93, 0.22)	0.12	117	0.22 (−0.72, 1.17)	0.64
BMC, g	226	−0.72 (−1.98, 0.54)	0.26	109	−1.07 (−2.98, 0.84)	0.27	117	−0.66 (−2.49, 1.16)	0.47
aBMD, g/cm2	226	−0.01 (−0.02, 0.01)	0.22	109	0.00 (−0.03, 0.02)	0.78	117	−0.02 (−0.037, 0.003)	0.10
Total hip
Bone area, cm2	223	−0.29 (−0.70, 0.12)	0.16	108	−0.32 (−0.97, 0.33)	0.33	115	−0.34 (−0.87, 0.20)	0.21
BMC, g	223	−0.32 (−0.92, 0.29)	0.31	108	−0.24 (−1.15, 0.67)	0.60	115	−0.48 (−1.35, 0.38)	0.27
aBMD, g/cm2	223	0.00 (−0.01, 0.01)	0.83	108	0.003 (−0.02, 0.02)	0.74	115	−0.01 (−0.03, 0.01)	0.47

¹Models adjusted for maternal age, parity, smoking, and BMI at baseline. aBMD, areal bone mineral density; BMC, bone mineral content; CTX, C-terminal telopeptide of type I collagen; LP, late pregnancy.

²Fisher-Yates transformed, SD.

³Conditional change in CTX (LP CTX adjusted for early-pregnancy CTX), z score.